Navigation Links
Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/12/2008

he conference can be obtained at http://www.rodmanandrenshaw.com .

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com .

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' prod
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...N, Nov. 25 Biotech firm Replikins ...ata from the 1918 pandemic through the prediction,...ic, today issued its latest biochemical analysis o... of the H1N1 ("Swine Flu") virus has dropped from ...ent outbreak in the spring of 2009 to resting non-...
(Date:11/25/2009)..., ,, BOCA RATON, Fla., Nov. 25 /PRNewswi...l year. Not so for BodyLogicMD. The nation,s larg...ns specializing exclusively in medically supervise... physicians in its network since November 20...s to add more physician-owned centers, including o...
(Date:11/25/2009)...BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biot...of vaccines, announced today that it executed,a jo...alian) Vaccine,Technology Co., Ltd. (Sinovac Dalia...mercialize human-use vaccines. Sinovac will contri...d commercializing world-class vaccines; the,other ...
(Date:11/25/2009)... Nov. 25 Ardea Bioscienc...ry D. Quart, Pharm.D., president and chief executi... Annual Health Care Conference. , ,Presentation d...Health Care Conference,Date: Tuesday, Decembe...on: The New York Palace Hotel, New York, NY,Webca...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...A, Calif., Nov. 20 Duska Therapeutics,Inc. (OTC B...ll today at,2:30 p.m. EST to review its drug devel...d quarter of 2008. Duska,s chief executive officer...re will be a question-and-answer session,immediate...nference, please call toll-free 800.895.0198,(dire...
...RY, Fla., Nov. 20 New Generation Biofuels Inc. (...ed into a Test Burn Agreement with Progress Energy...tary biofuel technology in utility boiler applicat...ion Biofuels to supply its biofuel for a test prog...ss Energy Florida,s Bartow Plant in St. Petersburg...
..., Nov. 20 Celsis International plc,(LSE: CEL.L), ...utions for,industry, today announced the launch of...he Celsis Innovate -- the company,s proven rapid m...This new rapid screening test kit,extends the Cels...reen Ultra,Heat Treated (UHT) and Extended Shelf L...
Other Biology Technology:Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 2Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 3Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 4Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 5Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 6Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 7New Generation Biofuels Announces Test Burn Agreement With Progress Energy Florida 2New Generation Biofuels Announces Test Burn Agreement With Progress Energy Florida 3Celsis Launches RapiScreen(TM) Beverage Microbial Screening System 2
(Date:11/30/2009)...cember 2009 print issue of The FASEB Journal cou...heir fertility that women have had since the 1960s...re androgenic hormones work in the testis to contr...s opens a promising avenue for the development of ... to those who cannot have children because of low ...
(Date:11/26/2009)...of using recordings of birdsong to accurately meas...t time sound recordings from a microphone array ha... species, populations. Because the new technique, ...nal of Applied Ecology , will also work with whale...lity to monitor whale and dolphin numbers. , Dev...
(Date:11/25/2009)...nia Institute of Technology (Caltech) have uncover...n the fruit fly, Drosophila melanogaster . , Th...nship between the neurotransmitter dopamine and at... described in the December issue of the journal N...bout 20,000 neurons and has long been considered a...
Breaking Biology News(10 mins):Ecologists sound out new solution for monitoring cryptic species 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4AEterna Zentaris to Raise US 245 5 Million from Institutional Investors at US 241 20 Per Share 14528 1AEterna Zentaris to Raise US 245 5 Million from Institutional Investors at US 241 20 Per Share 14528 2AEterna Zentaris to Raise US 245 5 Million from Institutional Investors at US 241 20 Per Share 14528 3ThermoGenesis Names Jorge Artiles Vice President Chief Quality and Regulatory Affairs Officer 5574 1ThermoGenesis Names Jorge Artiles Vice President Chief Quality and Regulatory Affairs Officer 5574 2ThermoGenesis Names Jorge Artiles Vice President Chief Quality and Regulatory Affairs Officer 5574 3Mirixa Corporation Announces MirixaEdge 28SM 29 5571 1Mirixa Corporation Announces MirixaEdge 28SM 29 5571 2
...o feed exclusively on blood, including human blood...ng. In a study published today in the open access ...esmodus rotondus could recognise recorded human br... could. Vampire bats feed on the same prey over se...that the bats use breathing sounds to identify the...
...ption, in which the enzyme RNA polymerase construc..., depends upon previously underappreciated section...se, according to work done with the bacterium E. c...ell by a team of bacteriologists from the Universi...rch about a key step in RNA synthesis has importan...
...n mountain range found surviving members of a spec...ller fungus wiping out amphibian populations in Ce...ould be the last population of the painted frog (A...es has survived the fungus, providing hope that ot...epidemic caused by a pathogenic fungus of unknown ...
Other Biology News:Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 2Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 3Colombian frog believed extinct found alive 2
50 ml Magnetic Separation Rack from New England Biolabs
Universal Amplification Primer from Invitrogen
Xylene cyanol FF, CI 43535 from Research Organics, Inc.
Sf9 Insect Cells from BD Biosciences Pharmingen
Biology Products: